OncoMatch/Clinical Trials/NCT04954599
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Is NCT04954599 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including CP-506 and Carboplatin for unspecified adult solid tumor, protocol specific.
Treatment: CP-506 · Carboplatin · Immune checkpoint inhibitor — A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in patients with HRD/FAD solid tumours or tumor types with high incidence of HRD/FAD in monotherapy or in combination with carboplatin or patients with solid tumour and oligoprogressive disease receiving immune checkpoint inhibitors (ICI): a phase I-IIa clinical trial
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: alkylating agent
Patients who were previously responsive to alkylating agent (Partial Response/Complete Response according to RECIST criteria)
Cannot have received: anticancer therapy (including radiotherapy)
Patients who have received anticancer therapy (including radiotherapy) within 4 weeks of inclusion
Cannot have received: anticancer therapy (including radiotherapy)
Exception: carboplatin
Patients who have received anticancer therapy (including radiotherapy) within 4 weeks of inclusion with exclusion of carboplatin
Cannot have received: anticancer therapy (including radiotherapy)
Exception: ICI
Patients who have received anticancer therapy (including radiotherapy) within 4 weeks of inclusion with exception of ICI
Cannot have received: allogeneic/autologous bone marrow or solid organ transplantation
Prior allogeneic/autologous bone marrow or solid organ transplantation
Lab requirements
Blood counts
ANC ≥ 1500/µL; Hemoglobin ≥ 9.0 g/dL; Platelets ≥ 100,000/µL
Kidney function
Creatinine ≤ 1.5 × ULN
Liver function
Total bilirubin ≤ 1.5 × ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels >1.5 × ULN; AST (SGOT) and ALT (SGPT) ≤ 2.5 × ULN (≤ 5 × ULN for participants with liver metastases)
Cardiac function
INR ≤ 1.5 × ULN (or within therapeutic ranges for participants on anticoagulant treatment)
Must have adequate organ and bone marrow function, defined as the following: ANC ≥ 1500 µL; Hemoglobin ≥ 9.0 g/dL; Platelets ≥ 100 000 µL; Total bilirubin ≤ 1.5 × ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels >1.5 × ULN; AST (SGOT) and ALT (SGPT) ≤ 2.5 × ULN (≤ 5 × ULN for participants with liver metastases); Creatinine ≤ 1.5 × ULN; Coagulation: INR ≤ 1.5 × ULN (or within therapeutic ranges for participants on anticoagulant treatment)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify